Bioasis Technologies Inc. (BIOAF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.74: the stock has moved about 74% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBioasis Technologies Inc. (BIOAF) trades at $0.0001. Bioasis Technologies Inc. is a development-stage biopharmaceutical company focused on creating treatments for neurological diseases by leveraging its xB3 platform to deliver therapeutics across the blood-brain barrier. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for BIOAF: BIOAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Bioasis Technologies Inc. (BIOAF) Healthcare & Pipeline Overview
Bioasis Technologies Inc. is a development-stage biopharmaceutical company specializing in neurological disease treatments. Its xB3 platform facilitates drug delivery across the blood-brain barrier, targeting conditions like brain metastases and glioblastoma. With strategic research collaborations, Bioasis aims to advance novel therapies for central nervous system disorders, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for BIOAF?
Bioasis Technologies Inc. presents a high-risk, high-reward investment opportunity centered on its xB3 platform technology for delivering therapeutics across the blood-brain barrier. The company's value is primarily driven by the potential success of its pipeline programs targeting brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Strategic collaborations with companies like Janssen Biotech and Neuramedy Co Ltd. provide validation of the xB3 platform and potential revenue streams through licensing and commercialization agreements. However, the company's negative profit margin of -7846.5% and gross margin of -45.6% highlight its reliance on future clinical and commercial success. Key catalysts include advancement of clinical trials and expansion of partnerships, while risks involve clinical trial failures, regulatory hurdles, and funding constraints.
Based on FMP financials and quantitative analysis
BIOAF Key Highlights
Bioasis Technologies Inc. is a development stage biopharmaceutical company focused on neurological diseases.
- The company's xB3 platform technology facilitates drug delivery across the blood-brain barrier.
- The company has a negative profit margin of -7846.5% reflecting its development stage.
- Gross margin is -45.6%, indicating that the company's cost of revenue exceeds its revenue.
- The company has a beta of 1.74, suggesting higher volatility compared to the market.
Who Are BIOAF's Competitors?
BIOAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $39.13 | +0.20% | $173B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $517.49 | -1.23% | $131B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $807.67 | +0.33% | $83.2B | 95 5-pillar |
| ARGX argenx SE | $869.33 | -0.50% | $54.7B | 97 5-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $227.66 | +1.62% | $31.0B | 91 5-pillar |
| RPRX Royalty Pharma plc | $64.76 | +1.41% | $28.4B | 75 5-pillar |
| GMAB Genmab A/S | $44.69 | +2.04% | $26.9B | 62 5-pillar |
| UTHR United Therapeutics Corporation | $592.84 | +0.91% | $25.2B | 98 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIOAF's Key Strengths?
Proprietary xB3 platform technology.
- Research collaborations with established pharmaceutical companies.
- Pipeline of drug candidates targeting unmet medical needs.
- Experienced management team with expertise in drug development.
What Are BIOAF's Weaknesses?
Development stage company with no approved products.
- High reliance on research and development funding.
- Negative profit margin and gross margin.
- Limited financial resources compared to larger pharmaceutical companies.
What Are the Key Risks for BIOAF?
Financial-distress signal — its Altman Z-Score of -42.04 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and regulatory approval delays.
- Competition from other pharmaceutical companies developing treatments for neurological diseases.
- Patent expiration and intellectual property challenges.
- Reliance on research and development funding.
- Negative profit margin and gross margin.
What Are BIOAF's Competitive Advantages?
- Proprietary xB3 platform technology for crossing the blood-brain barrier.
- Established research collaborations with pharmaceutical companies.
- Pipeline of drug candidates targeting specific neurological diseases.
- Intellectual property protection for xB3 technology and related applications.
What Does BIOAF Do?
Bioasis Technologies Inc., founded in 2006 and headquartered in New Haven, Connecticut, is a development stage biopharmaceutical company focused on creating innovative treatments for neurological diseases and disorders. The company's core technology is the xB3 platform, designed to transport therapeutic agents across the blood-brain barrier (BBB), a significant challenge in treating central nervous system (CNS) disorders. Bioasis is developing treatments for brain cancers, metabolic diseases, and neurodegenerative diseases. Its in-house development programs include xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases. Bioasis has established research collaborations to expand the application of its xB3 platform. These collaborations include partnerships with Aposense Limited for siRNA therapeutics delivery to treat CNS disorders, Oxyrane UK Ltd. to combine xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy delivery into the brain, and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on the xB3 platform. Additionally, Bioasis has a research collaboration and license agreement with Neuramedy Co Ltd. to develop and commercialize an xB3TM version of its antibody, Tomaralimab. As a development stage company, Bioasis is focused on advancing its pipeline through preclinical and clinical development, aiming to address unmet medical needs in the treatment of neurological disorders.
What Products and Services Does BIOAF Offer?
- Develop xB3 platform technology for drug delivery across the blood-brain barrier.
- Research and develop treatments for neurological diseases and disorders.
- Focus on therapies for brain metastases, glioblastoma, and neurodegenerative diseases.
- Collaborate with other companies to expand the application of xB3 technology.
- Develop symptomatic and disease-modifying treatments for CNS disorders.
- Seek to commercialize novel products based on the xB3 platform.
How Does BIOAF Make Money?
- Develop and out-license xB3 platform technology to other pharmaceutical companies.
- Generate revenue through research collaborations and licensing agreements.
- Advance internal drug development programs through preclinical and clinical trials.
- Potentially generate revenue through the sale of approved therapies.
What Industry Does BIOAF Operate In?
Bioasis Technologies Inc. operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The company focuses on developing treatments for neurological diseases, a market with substantial unmet needs and growth potential. The blood-brain barrier (BBB) presents a significant challenge in treating CNS disorders, making Bioasis's xB3 platform a potentially valuable asset. The biotechnology industry is driven by innovation, with companies constantly seeking to develop novel therapies and improve existing treatments. Competition includes companies such as BLFE, BNYN, EMYSF, GBLX, and GSTC, which are developing treatments for neurological disorders.
Who Are BIOAF's Key Customers?
- Pharmaceutical companies seeking drug delivery solutions for CNS disorders.
- Patients suffering from brain metastases, glioblastoma, and neurodegenerative diseases.
- Research institutions interested in collaborating on drug development.
- Strategic partners seeking to develop and commercialize xB3-based therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Earnings Track Record
Bioasis Technologies Inc. has missed Wall Street's EPS estimate in 2 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 60.7% above estimates on average.
Key Financial Metrics
Return on equity for Bioasis Technologies Inc. stands at 392.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.70 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Bioasis Technologies Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -42.04 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Bioasis Technologies Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Deborah Ann Rathjen. BIOAF has traded publicly since 2010.
BIOAF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
BIOAF Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Oct 21, 2019
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
BIOAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIOAF.
Price Targets
Wall Street price target analysis for BIOAF.
BIOAF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIOAF; grades run from A+ (80-100) to F (below 30).
Leadership: Deborah Ann Rathjen
CEO
Deborah Ann Rathjen serves as the CEO of Bioasis Technologies Inc. Her background includes extensive experience in the biotechnology and pharmaceutical industries. She has held leadership positions in various companies, focusing on drug development and commercialization. Her expertise spans strategic planning, business development, and clinical operations. Rathjen's experience includes roles in both large pharmaceutical companies and smaller biotechnology firms, providing her with a broad understanding of the industry landscape. She has a strong track record of driving innovation and growth in the healthcare sector.
Track Record: Under Deborah Ann Rathjen's leadership, Bioasis Technologies Inc. has focused on advancing its xB3 platform and pipeline of drug candidates. She has overseen the establishment of strategic collaborations with companies like Janssen Biotech and Neuramedy Co Ltd., which have validated the potential of the xB3 technology. Her tenure has been marked by efforts to secure funding for research and development and to navigate the regulatory landscape. She has focused on building a strong team and fostering a culture of innovation within the company.
BIOAF OTC Market Information
Bioasis Technologies Inc. trades on the OTC Other tier, which represents the lowest tier of the OTC market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often have limited regulatory oversight and reporting requirements. Companies on this tier may not meet minimum financial standards or listing requirements of major exchanges. This can result in less transparency and increased risk for investors. OTC Other stocks typically have lower trading volumes and wider bid-ask spreads compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Limited regulatory oversight and reporting requirements.
- Lower trading volume and wider bid-ask spreads.
- Increased price volatility.
- Potential for limited financial information.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Understand the company's capital structure and funding sources.
- Monitor news and press releases for updates on the company's progress.
- Consult with a financial advisor before investing.
- Research collaborations with established pharmaceutical companies.
- Development of proprietary xB3 platform technology.
- Pipeline of drug candidates targeting specific neurological diseases.
- Experienced management team with expertise in drug development.
Bioasis Technologies Inc. Healthcare Stock: Key Questions Answered
What do analysts say about BIOAF stock?
As of 2026-03-16, there is no readily available analyst consensus on BIOAF stock due to its OTC listing and development stage.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.